JNPMEDI officially announces its entry into the domestic decentralized clinical trial (DCT) market.

Maven DCT Suite

JNPMEDI will accelerate the development of the "Maven DCT Suite" family, a Decentralized Clinical Trial (DCT) solution, with the aim of launching it in the first half of 2022.

Due to the COVID-19 pandemic, non-face-to-face decentralized clinical trials are rapidly becoming a trend overseas. In addition, with the development of advanced technologies such as IoT, untact, and big data, the need to conduct clinical trials in a different way than before is increasing day by day by day.

In Korea, regulators such as the Ministry of Food and Drug Safety have recently started to advance regulations due to changes in the clinical trial environment, showing changes in perception of decentralized clinical trials.

According to the Ministry of Food and Drug Safety on December 21, the government recently selected research on advanced regulations due to changes in the post-COVID clinical trial environment as a R&D project and decided to seek ways to improve clinical trial regulations. The KFDA believes that it is urgent to establish a "private-led public interest clinical trial (regulatory) platform" that applies and tests various regulations and technologies to respond to the current approach to the design and performance of clinical trials.

JNPMEDI is proactively providing DCT services in anticipation of changes in domestic clinical trials. In June, the eCOA (Clinical Outcome Assessment) solution, which receives data from clinical testers through mobile devices, was applied to clinical trials at top university hospitals in Korea, and related technologies are also actively applied to digital treatment clinical trials.

JNPMEDI, which is considered to have differentiated capabilities in the market by responding quickly to non-face-to-face trends, recently attracted Seed investment from Kakao Ventures, Ajou IB Investment, Murex Partners, and Gentium Partners.

Industry experts positively evaluated that the Ministry of Food and Drug Safety's move to improve regulations will have a great effect on fostering digital healthcare companies along with the development of domestic clinical trials.